Hyperbaric Oxygen Therapy

What is Hyperbaric Oxygen Therapy?

Hyperbaric oxygen therapy (HBOT) is a treatment that involves breathing oxygen at pressures above normal atmospheric pressure. The combination of increased pressure and elevated oxygen concentration substantially increases the amount of oxygen dissolved in the blood plasma, allowing oxygen to reach tissues that may be poorly served by normal circulation.

HBOT addresses tissue oxygenation issues, the physiological conditions described on the Tissue Oxygenation and Our Health page. By increasing oxygen availability at the tissue level, HBOT supports healing processes that depend on adequate cellular oxygen supply.

The Basic Physics

Normal atmospheric pressure at sea level is 1 atmosphere absolute (ATA). Under normal conditions, blood carries oxygen primarily bound to hemoglobin in red blood cells, with a small amount dissolved directly in blood plasma.

Hyperbaric therapy increases both the pressure and, in some configurations, the concentration of oxygen breathed. Under increased pressure with oxygen-enriched air:

  • Increased dissolved oxygen: More oxygen dissolves directly in blood plasma.
  • Greater tissue diffusion: Dissolved oxygen can reach tissues that red blood cells cannot easily access.
  • Improved cellular respiration: Cells receive oxygen quantities that support normal function even in compromised areas.
  • Enhanced healing capacity: Multiple oxygen-dependent healing processes function more effectively.

Different pressure levels and oxygen concentrations produce different physiological effects. The two primary categories of HBOT devices operate at substantially different specifications.

Two Categories of Hyperbaric Chambers

Two distinct categories of hyperbaric chambers serve different applications:

  1. Hard-shell chambers: Steel-enclosed chambers operating at 2.0 to 3.0 ATA with 100% medical-grade oxygen. Used in clinical settings for FDA-approved medical indications and various off-label therapeutic applications.
  2. Soft-shell chambers: Portable fabric chambers operating at 1.3 to 1.5 ATA, typically with ambient air or moderately oxygen-enriched air. Used primarily for wellness applications, general recovery, and home use.

Both categories are legitimate for their respective purposes, but they differ substantially in pressure, oxygen delivery, regulatory status, and appropriate applications. Understanding these differences is essential for choosing the right approach for specific needs.

Hard-Shell Hyperbaric Chambers

Hard-shell chambers represent the medical standard for hyperbaric oxygen therapy. They are the type of chamber used in hospitals, clinics, and specialized wound care facilities.

Technical Specifications

  • Construction: Steel-enclosed pressure vessels meeting ASME PVHO-1 (Pressure Vessels for Human Occupancy) standards.
  • Operating pressure: Typically 2.0 to 3.0 ATA, equivalent to being 33 to 66 feet underwater.
  • Oxygen delivery: 100% medical-grade oxygen (USP 99% purity).
  • Session duration: Typically 60 to 120 minutes.
  • Facility requirements: Installation requires meeting NFPA 99 Health Care Facilities Code and NFPA 101 Life Safety Code standards.
  • Physiological delivery: Arterial oxygen levels can reach approximately 1,800 mmHg during sessions, roughly 8 times higher than atmospheric oxygen delivery.

FDA-Approved Indications

The FDA has approved hard-shell HBOT at 2.0+ ATA with 100% oxygen for 14 specific medical conditions:

  • Air or gas embolism
  • Carbon monoxide poisoning
  • Clostridial myositis and myonecrosis (gas gangrene)
  • Crush injury, compartment syndrome, and acute traumatic ischemias
  • Decompression sickness
  • Enhancement of healing in select problem wounds (diabetic foot ulcers, non-healing wounds)
  • Severe anemia (when transfusion is not possible)
  • Intracranial abscess
  • Necrotizing soft tissue infections
  • Osteomyelitis (refractory)
  • Delayed radiation injury (soft tissue and bony necrosis)
  • Compromised grafts and flaps
  • Acute thermal burn injury
  • Idiopathic sudden sensorineural hearing loss

These indications are supported by clinical evidence and are typically covered by insurance when prescribed by a qualified physician.

Off-Label Applications

Hard-shell HBOT is also used off-label for numerous conditions supported by emerging clinical evidence:

  • Traumatic brain injury and post-concussion syndrome
  • Stroke recovery
  • Long COVID and post-viral syndromes
  • Neurological conditions including cerebral palsy
  • Autism spectrum considerations
  • Age-related conditions and cognitive support
  • Athletic recovery in specific circumstances

Off-label use is legal but generally requires out-of-pocket payment. Clinical HBOT centers offer these applications with appropriate medical supervision.

Clinical Setting Requirements

Hard-shell HBOT typically requires:

  • Physician prescription and supervision.
  • Trained hyperbaric technicians: Operators must have specialized certification.
  • Medical clearance: Pre-treatment evaluation for contraindications.
  • Facility infrastructure: Fire safety, oxygen handling, and emergency response capabilities.
  • Session cost: Typically $250 to $600 per session at clinical facilities.

Soft-Shell Hyperbaric Chambers

Soft-shell chambers, also called mild hyperbaric oxygen therapy (mHBOT) chambers, represent an accessible form of pressure therapy suitable for home use and general wellness applications.

Technical Specifications

  • Construction: Portable fabric chambers with pressure-relief valves and safety zippers.
  • Operating pressure: Typically 1.3 to 1.5 ATA, equivalent to being at approximately 12 to 15 feet underwater.
  • Air delivery: Ambient air or moderately oxygen-enriched air (typically 24 to 40% oxygen when concentrators are used).
  • Session duration: Typically 60 to 90 minutes.
  • Portability: Deflatable for storage and relocation.
  • Physiological delivery: Arterial oxygen levels reach approximately 230 mmHg during sessions with ambient air, higher with oxygen enrichment.

FDA Regulatory Position

Soft-shell chambers have a specific and important regulatory status:

  • FDA 510(k) clearance: Cleared as devices for acute mountain sickness only.
  • Other applications: All other applications are considered off-label use.
  • Oxygen restrictions: The FDA specifies that soft-shell chambers are cleared for use with ambient air. Use with supplemental oxygen concentrators is common in clinical practice but is not part of the original FDA clearance.

This regulatory position does not indicate that soft-shell chambers lack utility. It reflects that the FDA has only formally reviewed the technology for the acute mountain sickness indication. Wellness and off-label applications continue based on emerging research and clinical practice.

Documented and Emerging Applications

Research on soft-shell mHBOT specifically is more limited than research on hard-shell HBOT, but a growing evidence base supports several applications:

  • Inflammation reduction: A 2025 comparative study found that 1.3 ATA reduced 21 inflammatory cytokines, with effects comparable to higher pressures in some measures.
  • General recovery from physical exertion: Applications for post-exercise recovery and daily wellness use.
  • Cognitive support in some populations: Research on mild cognitive support and mental clarity.
  • Chronic fatigue and low-grade inflammatory conditions: Wellness applications for individuals with persistent fatigue.
  • Acute mountain sickness: The specific FDA-cleared indication.

Additional applications are used based on the broader HBOT research base, with the understanding that effects at 1.3 to 1.5 ATA may be more modest than effects at 2.0 to 3.0 ATA.

Home Use Considerations

Soft-shell chambers are designed for home use, which introduces specific considerations:

  • No prescription required: Available for direct consumer purchase.
  • User-operated: No specialized technician needed for typical wellness use.
  • Cost: Home units typically range from $4,000 to $25,000 for personal ownership.
  • Session cost: No per-session fee for home units after initial purchase.
  • Regular use accessibility: Enables consistent daily or weekly sessions that would be impractical at clinical facilities.

The accessibility and repeatability of home mHBOT represent its primary practical advantage for wellness applications.

Mechanisms of Action

Both hard-shell HBOT and soft-shell mHBOT produce physiological effects through overlapping mechanisms, though the magnitude of effects differs based on pressure and oxygen delivery.

Increased Tissue Oxygenation

The primary mechanism of all HBOT is increased oxygen availability at the tissue level:

  • Plasma-dissolved oxygen: Under pressure, more oxygen dissolves directly in blood plasma.
  • Diffusion distance: Dissolved oxygen can diffuse farther from blood vessels than hemoglobin-bound oxygen.
  • Reach compromised tissues: Oxygen can reach areas with impaired circulation.
  • Support metabolic demands: Tissues under repair have elevated oxygen requirements that increased delivery can meet.

Higher pressures produce proportionally greater increases in dissolved oxygen. At 2.4 ATA with 100% oxygen, dissolved plasma oxygen increases by approximately 20-fold compared to normal atmospheric breathing. At 1.3 ATA with ambient air, dissolved plasma oxygen increases by approximately 30 to 40%.

Angiogenesis (New Blood Vessel Formation)

Elevated tissue oxygen promotes formation of new blood vessels through:

  • Upregulation of vascular endothelial growth factor (VEGF)
  • Enhanced fibroblast function
  • Improved endothelial cell activity
  • Support of pericyte function

Angiogenesis benefits chronic wound healing, radiation injury recovery, and any condition requiring restoration of tissue perfusion.

Anti-Inflammatory Effects

Elevated tissue oxygen produces anti-inflammatory effects through:

  • Modulation of inflammatory cytokines
  • Reduced neutrophil adhesion to damaged endothelium
  • Support of macrophage function toward healing rather than pro-inflammatory states
  • Reduction of oxidative stress markers with regular sessions

Anti-inflammatory effects have been documented at both clinical HBOT pressures (2.0+ ATA) and mild pressures (1.3 to 1.5 ATA).

Stem Cell Mobilization

HBOT has been documented to mobilize stem cells from bone marrow. This effect appears to be dose-dependent, with higher pressures producing greater mobilization. Increased circulating stem cells support tissue repair and regeneration.

Antimicrobial Effects

At clinical HBOT pressures (2.0 ATA and above with 100% oxygen), tissue oxygen levels become directly toxic to anaerobic bacteria and enhance immune cell antimicrobial activity. These antimicrobial effects are the basis for HBOT use in serious infections including necrotizing fasciitis and refractory osteomyelitis.

Antimicrobial effects at mild pressures (1.3 ATA) are considerably less pronounced. This is one area where the pressure difference between hard-shell and soft-shell chambers produces qualitatively different, not just quantitatively different, effects.

Mitochondrial Support

Both HBOT and mHBOT appear to support mitochondrial function through improved oxygen availability for aerobic metabolism. This supports cellular energy production in tissues where mitochondrial function may be compromised.

Neurological Applications

Research on HBOT for neurological conditions documents effects on:

  • Cerebral blood flow
  • Neurogenesis (new neuron formation)
  • Reduction of neuroinflammation
  • Support of blood-brain barrier integrity
  • HIF-1α pathway modulation

Most neurological research has used hard-shell HBOT at 1.5 to 2.4 ATA, though emerging research is examining effects at mild pressures.

Choosing Between Hard-Shell and Soft-Shell

The choice between hard-shell and soft-shell hyperbaric chambers depends on several factors, including the specific application, setting, and practical considerations.

When Hard-Shell HBOT is Typically Appropriate

Hard-shell HBOT is generally the appropriate choice for:

  • FDA-approved medical conditions: Any of the 14 FDA-approved indications that require higher pressures and 100% oxygen can only be provided by hard-shell chambers.
  • Serious wound healing challenges: Diabetic foot ulcers, radiation-induced tissue damage, and chronic non-healing wounds respond best to clinical HBOT protocols.
  • Serious infections: Antimicrobial effects require higher pressures.
  • Significant neurological injury recovery: Post-stroke and post-TBI recovery protocols use clinical HBOT.
  • Insurance-covered treatment: Insurance coverage generally requires medically necessary clinical HBOT.
  • Physician-directed treatment protocols: Specific medical conditions requiring supervised care.

Hard-shell HBOT typically involves scheduled appointments at specialized facilities, physician oversight, and defined treatment courses (often 40 sessions over 8 weeks for many indications).

When Soft-Shell mHBOT is Typically Appropriate

Soft-shell mHBOT is generally the appropriate choice for:

  • General wellness applications: Daily or regular use for overall recovery and wellness.
  • Home-based use: Regular sessions from home rather than clinical appointments.
  • Post-exercise recovery: Athletic recovery and physical exertion recovery.
  • Chronic low-grade inflammation: Ongoing management rather than acute treatment.
  • Cognitive support and mental clarity: Regular wellness use.
  • Long-term integration: Building HBOT into a wellness routine over months or years.
  • Individuals without access to hard-shell facilities: In areas without clinical HBOT options.
  • Cost considerations over time: After the initial purchase, there are no per-session costs.
  • Acute mountain sickness: The specific FDA-cleared indication.

Soft-shell mHBOT is not appropriate as a substitute for clinical HBOT when a medical condition requires the higher pressures and oxygen concentrations of hard-shell treatment.

Complementary Rather Than Competing

For many individuals, both categories can serve legitimate roles at different times:

  • Clinical HBOT for acute medical needs when specific conditions require higher-pressure treatment.
  • Home mHBOT for ongoing wellness support between or after clinical treatment courses.
  • Prevention and general wellness. Home mHBOT for maintenance when clinical HBOT is not indicated.
  • Post-injury recovery. Both may apply at different phases of recovery.

The two categories should be understood as different tools with different applications rather than competing versions of the same treatment.

Historical and Regulatory Development

Hyperbaric medicine has developed through several distinct phases since its origins.

Early Development

Hyperbaric therapy dates to the seventeenth century, when British physician Nathaniel Henshaw built the first chamber in 1662. Early applications were largely empirical, without understanding of the underlying physiology.

Modern Clinical HBOT

Modern hyperbaric oxygen therapy developed through military and industrial applications:

  • 1917: German scientists used pressurized oxygen to treat decompression sickness in divers.
  • 1930s: Development of standard treatment protocols for decompression illness.
  • 1950s and 1960s: Expansion into treatment of gas gangrene and carbon monoxide poisoning.
  • 1970s: Establishment of the Undersea and Hyperbaric Medical Society (UHMS) to standardize clinical practice.
  • 1980s to present: Progressive expansion of FDA-approved indications and off-label clinical applications.

mHBOT Development

Soft-shell chamber technology developed later:

  • 1990s: Development of portable soft-shell chambers primarily for treatment of acute mountain sickness in remote mountaineering.
  • 2000s: Expansion into wellness applications and home use.
  • 2005: Notable FDA 510(k) clearance (K051759) for mild hyperbaria at 1.3 ATA for acute mountain sickness.
  • 2010s to present: Growing availability of home units and emerging clinical use for wellness applications.

Current Regulatory Framework

The current regulatory landscape reflects the distinction between clinical HBOT and wellness mHBOT:

  • Hard-shell chambers require FDA clearance for specific medical device indications and are typically used in clinical facilities meeting healthcare facility standards.
  • Soft-shell chambers are FDA-cleared only for acute mountain sickness but are legally available for consumer purchase.
  • Clinical use of both types for off-label indications is permitted based on physician judgment.
  • Marketing claims for both types must not exceed cleared indications.

The Undersea and Hyperbaric Medical Society, the professional society governing clinical HBOT practice, does not currently recognize soft-shell chambers as meeting clinical HBOT standards but does not oppose wellness use.

Session Protocols

Session parameters differ significantly between hard-shell and soft-shell HBOT.

Hard-Shell HBOT Sessions

Clinical HBOT sessions typically follow standardized protocols:

  • Duration: 60 to 120 minutes at pressure.
  • Frequency: For most FDA-approved indications, typically 5 days per week for 4 to 8 weeks (20 to 40 sessions total).
  • Compression: Gradual pressurization over 10 to 15 minutes.
  • Treatment phase: Sustained pressure with 100% oxygen breathing.
  • Air breaks: 5-minute periods of breathing ambient air every 20 to 30 minutes to reduce the risk of oxygen toxicity.
  • Decompression: Gradual return to normal pressure over 10 to 15 minutes.

Clinical sessions require physician oversight and monitoring by trained hyperbaric technicians.

Soft-Shell mHBOT Sessions

Home mHBOT sessions typically follow simpler protocols:

  • Duration: 60 to 90 minutes at pressure.
  • Frequency: Varies by user; commonly 3 to 7 sessions per week for wellness applications.
  • Compression: Gradual pressurization over 5 to 10 minutes.
  • Treatment phase: Sustained pressure with ambient or moderately oxygen-enriched air.
  • Decompression: Gradual return to normal pressure over 5 to 10 minutes.

Home mHBOT sessions do not typically require air breaks because oxygen concentrations are lower and toxicity risk is minimal.

Ear Pressure Equalization

Both hard-shell and soft-shell sessions require attention to ear pressure equalization during compression and decompression:

  • Yawning or swallowing: Simple techniques often sufficient.
  • Valsalva maneuver: Gently blowing against a pinched nose and closed mouth.
  • Frenzel maneuver: Advanced equalization technique.
  • Slow compression rates: Gradual pressure changes allow easier equalization.

Individuals with sinus congestion or ear tube dysfunction may find equalization challenging and should postpone sessions until issues resolve.

Safety, Side Effects, and Contraindications

Hyperbaric therapy has a well-established safety profile when used according to appropriate guidelines, but specific risks and contraindications require attention.

Common Side Effects

Reported side effects are typically mild and preventable:

  • Ear discomfort: From pressure changes; usually manageable with equalization techniques.
  • Sinus pressure: Similar to changes experienced during air travel.
  • Temporary vision changes: Myopia (nearsightedness) can develop with frequent hard-shell sessions but typically resolves after treatment ends.
  • Fatigue: Some users experience tiredness after sessions.
  • Claustrophobia: Some individuals experience anxiety in enclosed spaces.
  • Barotrauma: Rarely, ear or sinus injury from pressure changes.

Absolute Contraindications

Certain conditions are absolute contraindications to HBOT and mHBOT of any type. Sessions should not be conducted in the presence of:

  • Untreated pneumothorax: A collapsed lung is a medical emergency, and hyperbaric therapy could be fatal in this circumstance.
  • Concurrent use of certain chemotherapy agents: Including doxorubicin and bleomycin, which have life-threatening interactions with hyperbaric oxygen.
  • Uncontrolled seizure disorders: Oxygen toxicity can trigger seizures in susceptible individuals.
  • Severe congestive heart failure: Pressure changes and increased oxygen delivery can worsen fluid balance.

Situations Requiring Medical Consultation

The following circumstances require consultation with a healthcare provider before beginning hyperbaric therapy:

  • Pregnancy: Risk-benefit analysis needed for specific circumstances.
  • Diabetes: Blood glucose monitoring recommended; some users experience hypoglycemia during sessions.
  • Emphysema and severe COPD: Air trapping can create localized pressure issues.
  • Recent thoracic surgery: Chest surgery may create risk of pneumothorax.
  • Middle ear surgery or dysfunction: May prevent adequate pressure equalization.
  • Fever: Increases oxygen toxicity risk.
  • Severe claustrophobia: May require desensitization or medication.
  • Recent optic neuritis: Oxygen exposure may worsen certain optic conditions.
  • Cochlear implants or other electronic implants: Compatibility must be verified.
  • Certain lung conditions: Some pulmonary conditions require specialized evaluation.

Oxygen Toxicity Considerations

Oxygen toxicity is a specific consideration for HBOT:

  • Central nervous system toxicity: Can occur at pressures above 2.0 ATA with prolonged exposure; symptoms include visual changes, tingling, and rarely seizures.
  • Pulmonary oxygen toxicity: Can occur with prolonged high-oxygen exposure; typically requires many hours of sustained exposure.
  • Prevention: Air breaks during hard-shell sessions and appropriate session duration limits prevent toxicity.
  • mHBOT considerations: Oxygen toxicity risk is minimal at 1.3 to 1.5 ATA with ambient air but requires attention if oxygen concentrators are used.

Fire Safety

Hyperbaric environments have specific fire safety considerations:

  • Oxygen-enriched atmospheres increase fire risk.
  • No flammable materials, including certain clothing fabrics, hair products, and cosmetics, are permitted in clinical HBOT chambers.
  • Hard-shell facility standards include fire suppression and specific electrical safety requirements.
  • Home mHBOT users should follow manufacturer safety guidelines regarding materials and environment.

General Guidance

Individuals with diagnosed medical conditions, those taking prescription medications, or those in any risk category should consult a healthcare provider before beginning hyperbaric therapy. Both hard-shell and soft-shell chambers require appropriate respect for the physiological effects they produce.

Summary

Hyperbaric oxygen therapy delivers oxygen at pressures above normal atmospheric pressure, addressing tissue oxygenation issues that can impair healing, contribute to chronic inflammation, and affect multiple aspects of aging and recovery.

Two distinct categories of hyperbaric chambers serve different purposes. Hard-shell chambers operating at 2.0 to 3.0 ATA with 100% oxygen represent the medical standard, with FDA approval for 14 specific indications and extensive off-label clinical use. Soft-shell chambers operating at 1.3 to 1.5 ATA with ambient or oxygen-enriched air serve wellness applications, general recovery, and home use, with FDA clearance for acute mountain sickness and growing evidence for anti-inflammatory and recovery applications.

The two categories are complementary rather than competing. Choice between them depends on the specific application, whether medical treatment or wellness support is needed, the setting where therapy will occur, and individual health considerations.

Both categories operate through overlapping mechanisms including increased tissue oxygenation, angiogenesis, anti-inflammatory effects, mitochondrial support, and stem cell mobilization. Effects at higher pressures are generally more pronounced, and certain applications (particularly serious infections and severe wound healing) require the higher pressures only hard-shell chambers can deliver.

Safe use of both categories requires attention to contraindications, particularly untreated pneumothorax as an absolute contraindication. Consultation with a healthcare provider is recommended before beginning hyperbaric therapy, particularly for individuals with cardiovascular, pulmonary, or ear conditions.

Additional Resources
View Products